TLRY — Tilray Brands, Inc.

Tilray Brands (TLRY) Q4 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $915.5 million for fiscal 2026, an 11% increase from $821.3 million in fiscal 2025. On a pro forma basis, the company is now approximately a $1.2 billion revenue entity.
• Adjusted EBITDA: Increased 11% to $61.1 million, with an adjusted EBITDA margin of 6.7%. Excluding temporary fuel surcharges, adjusted EBITDA would have been $63.4 million.
• Net Loss: Improved significantly to $105.2 million, or $1.09 per share, compared to a loss of $2.2 billion in the prior year, primarily due to the absence of a non-cash impairment charge.
• Cash Position: Ended the year with approximately $235 million in cash and marketable securities, with net debt reduced to less than $1 million, a 95% improvement year-over-year.
• Gross Profit: Increased 8% to $260.4 million, with a gross margin of 28%.

2. Strategic Updates and Business Highlights

• Diversification: Tilray has transformed into a diversified global consumer products and pharmaceutical distribution company, with leadership in cannabis, beverages, hospitality, and wellness.
• Acquisition of BrewDog: Acquired for approximately $54 million, contributing $51.1 million in revenue during Q4. BrewDog is expected to enhance Tilray's beverage platform significantly.
• International Expansion: Strong growth in international cannabis revenue, up 34% to approximately $85 million, driven by demand in Germany, Poland, and the U.K.
• Canadian Cannabis Leadership: Maintained leadership in the Canadian market with a 5% increase in adult-use cannabis revenue, driven by innovation in product formats like pre-rolls and edibles.

3. Forward Guidance and Outlook

• Fiscal 2027 Guidance: Expected adjusted EBITDA between $68 million and $75 million, representing a double-digit increase from fiscal 2026. The company anticipates continued growth in international operations, particularly in Europe.
• Revenue Run Rate: Projected combined international business revenue to reach approximately $700 million, or 60% of consolidated revenue.

4. Challenges and Points of Concern

• Price Compression: International cannabis revenue faced approximately $21 million in price compression, impacting profitability.
• Canadian Market Dynamics: Canadian medical cannabis revenue decreased 5% due to changes in Veterans Affairs reimbursement, with expectations of a $4 million annual impact.
• Beverage Segment Decline: Organic growth in the beverage segment (excluding BrewDog) was down 17%, attributed to brand rationalization and broader industry dynamics.
• Regulatory Risks: Uncertainty surrounding U.S. cannabis legalization and regulatory frameworks poses risks to future growth opportunities.

5. Notable Q&A Insights

• Integration and Growth: CEO Irwin Simon emphasized the interconnectedness of Tilray's diverse business segments, highlighting the potential for cross-category synergies.
• U.S. Market Strategy: Simon expressed caution regarding U.S. market entry, awaiting clearer regulatory paths before pursuing acquisitions or expansions.
• Beverage Business Confidence: The company is optimistic about improving its beverage brands, citing recent operational changes and new product introductions.
• International Cannabis Growth: Simon noted that securing supply and expediting permit processes are critical for sustaining growth in international markets.

Overall, Tilray Brands showcased significant progress in fiscal 2026, driven by strategic acquisitions and a diversified business model, while also facing challenges in pricing and market dynamics that could impact future performance.